Report of the Independent Allocation of Vaccines Group on the allocation of COVAX Facility secured vaccines: 15 July 2021

This report covers the allocation of Pfizer BioNTech - Comirnaty (“Pfizer”), for which WHO issued an Emergency Use Listing (EUL) on 31 December 2020. The available supply of Pfizer product for allocation in this round included:

• 12 190 230 doses secured though the COVAX Facility’s advance purchase agreement (APA) with the manufacturer, and
• 59 999 940 doses made available to the COVAX Facility for Q3-2021 allocation to AMC participants as well as six SFPs in the African Union through a procurement facilitated by the government of the United States of America (USG)

This allocation round took into account the cumulative coverage achieved by each participant through previous allocation rounds (Rounds 1 to 4) and as a result of dose donations executed through the COVAX Facility (including from France, New Zealand, the United States and Japan).

Supply needs for the COVAX Humanitarian Buffer (HB) were not factored into this allocation round, as this round only allocated volumes of the Pfizer product. The 5% of doses which would normally be allocated to the Humanitarian Buffer will be made up in future allocation rounds when more programmatically suitable vaccines are available.